Compare · NRXS vs TMDX
NRXS vs TMDX
Side-by-side comparison of Neuraxis Inc. (NRXS) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.57B, about 29.6x NRXS ($86.8M).
- Over the past year, NRXS is up 139.3% and TMDX is down 32.5% - NRXS leads by 171.8 points.
- TMDX has been more active in the news (5 items in the past 4 weeks vs 2 for NRXS).
- TMDX has more recent analyst coverage (18 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- TransMedics Group Inc.
- Price
- $6.94-1.70%
- $71.33-3.87%
- Market cap
- $86.8M
- $2.57B
- 1M return
- -2.80%
- -5.62%
- 1Y return
- +139.31%
- -32.53%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2019
- News (4w)
- 2
- 5
- Recent ratings
- 0
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest NRXS
- SEC Form S-8 filed by Neuraxis Inc.
- Neuraxis Inc. filed SEC Form 8-K: Other Events
- Neuraxis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- Director Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)
- SEC Form DEFA14A filed by Neuraxis Inc.
- SEC Form DEF 14A filed by Neuraxis Inc.
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)